# Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

> **NCT05848765** · PHASE2 · RECRUITING · sponsor: **University of Birmingham** · enrollment: 284 (estimated)

## Conditions studied

- Relapsed Follicular Lymphoma
- Refractory Follicular Lymphoma

## Interventions

- **DRUG:** Epcoritamab
- **DRUG:** Lenalidomide
- **DRUG:** Rituximab
- **DRUG:** Obinutuzumab
- **DRUG:** Bendamustine
- **DRUG:** Vincristine
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Prednisone
- **DRUG:** Investigation agent 2
- **DRUG:** Investigation agent 3

## Key facts

- **NCT ID:** NCT05848765
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-04
- **Primary completion:** 2029-05-31
- **Final completion:** 2031-11-30
- **Target enrollment:** 284 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05848765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05848765, "Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05848765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*